Şunu mu demek istediniz:
harm » farm (Aramayı Genişlet)
resolve. » resolved. (Aramayı Genişlet)
revolvesd. » revolves. (Aramayı Genişlet), resolved. (Aramayı Genişlet), evolved. (Aramayı Genişlet)
Gösterilen 1 - 20 sonuçlar arası kayıtlar. 142 sonuç. Aranan kelime 'harm is (((((resolve. OR resolve.) OR evolveddssdds.) OR revolvesd.) OR involved.) OR involves.)*', Sorgu süresi: 0.11s Sonuçları Daraltın
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl Yazar: Elham Mazarei (4508746)

    Baskı/Yayın Bilgisi 2025
    Konular:
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  12. 12
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  15. 15
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  17. 17
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  18. 18
    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.

    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. Yazar: Diana M. Hendrickx (1507435)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:
  20. 20
    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB).

    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB). Yazar: Zhizhong Wang (838758)

    Baskı/Yayın Bilgisi 2025
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: